Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of Oltipraz.

Several preclinical studies indicated that Oltipraz appears to be one of the most potent cancer chemopreventive agents. Pharmacological studies in humans provided substantial amounts of information related to doses and schedules. Oltipraz has been reported to induce phase II drug-metabolizing enzymes.